Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2022
Morphic Holding, Inc. (MORF)
Last morphic holding, inc. earnings: 11/12 04:24 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
Continued enrollment of EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis Announced key appointments and advancements in leadership team Ended second quarter 2022 with $397.6 million in cash and equivalents Cash runway extended into second half of 2025 WALTHAM, Mass. , Aug. 03, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the second quarter of 2022. Second Quarter 2022 and Recent Corporate Highlights Continued enrollment of EMERALD-1 (MORF-057-201) phase 2a study EMERALD-1, an open-label multi-center study of MORF-057 enrolling up to 35 patients with moderate to severe ulcerative colitis (UC), who will receive 100 mg BID (twice daily), continues to progress as planned EMERALD-2 (MORF-057-202), a global phase 2b double-blind randomized placebo-contro
Show less
Read more
Impact Snapshot
Event Time:
MORF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MORF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MORF alerts
High impacting Morphic Holding, Inc. news events
Weekly update
A roundup of the hottest topics
MORF
News
- MORF NEWS: Johnson Fistel has Commenced an Investigation on Behalf of Morphic Holding Company ShareholdersGlobeNewswire
- Morphic Holding, Inc. (MORF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAccesswire
- Morphic Holding, Inc. (MORF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAccesswire
- Morphic Holding, Inc. (MORF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsBusiness Wire
- Morphic Holding, Inc. (MORF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAccesswire
MORF
Earnings
- 11/3/23 - Beat
MORF
Analyst Actions
- 3/8/24 - Canaccord Genuity
MORF
Sec Filings
- 3/28/24 - Form 4
- 3/19/24 - Form 4
- 3/19/24 - Form 3
- MORF's page on the SEC website